Biofil Chemicals & Pharmaceuticals Ltd has moved to retain Mr. Ashok Kumar Ramawat as a Non-Executive Independent Director beyond the statutory age limit of 75 years. The company’s Board of Directors approved the continuation on August 11, 2026, based on the recommendation of the Nomination and Remuneration Committee. This move ensures continuity in governance for a director with 46 years of experience in the pharmaceutical industry, though it requires explicit shareholder consent to remain valid under regulatory frameworks.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-PoD2/I/3762/2026 dated January 30, 2026. Specifically, the filing addresses Sub-Para 7 of Para A of Part A of Schedule III of the Listing Regulations, which mandates continuous disclosure of material events regarding directorships.

Mr. Ramawat’s tenure is contingent upon approval by shareholders through a Special Resolution at the company’s ensuing 41st Annual General Meeting, as required under Regulation 17(1A) of the Listing Regulations. Until this approval is granted, his continuation remains provisional. The Board meeting that approved this recommendation commenced at 04:30 P.M. and concluded at 05:30 P.M. on August 11, 2026.

Mr. Ramawat holds a Bachelor’s Degree in Science and brings 46 years of post-qualification experience with significant exposure to the pharmaceutical sector. He was originally appointed as a Non-Executive Independent Director effective August 25, 2020. The filing confirms that he is not related to any other Directors or Key Managerial Personnel of the company, ensuring independence in his role.

The company also confirmed compliance with BSE Circular No. LIST/COMP/14/2018-19 and NSE Circular No. NSE/CML/2018/24, both dated June 20, 2018. These circulars require listed entities to confirm that directors are not debarred from holding office by SEBI or any other regulatory or statutory authority. The disclosure was submitted in both XBRL and PDF formats through the stock exchanges’ filing utilities within the prescribed time limits.

Governance Implications

The retention of senior independent directors beyond the age of 75 is a strategic governance decision often aimed at preserving institutional memory and sector-specific expertise. In this case, Mr. Ramawat’s four decades of experience in the pharmaceutical industry likely provide valuable oversight capabilities. However, the requirement for a Special Resolution underscores the regulatory emphasis on shareholder agency in such exceptions to standard tenure rules. Investors will have the opportunity to vote on this matter during the 41st Annual General Meeting, determining whether the Board’s recommendation aligns with their expectations for board composition and independence.

Biofil Chemicals and Pharmaceuticals Limited reported a net profit of ₹278.60 crore for the financial year ended March 31, 2026, a significant increase from ₹55.78 crore in the previous year. The company's revenue from operations for FY26 stood at ₹2839.52 crore, down from ₹3340.22 crore in FY25. The Board of Directors approved the audited financial results for the fourth quarter and the financial year ended March 31, 2026, in a meeting held on May 30, 2026.

The statutory auditors, Maheshwari & Gupta, Chartered Accountants, issued an unmodified opinion on the standalone financial results. The audit was conducted in accordance with the Standards on Auditing specified under section 143(10) of the Companies Act, 2013. The company confirmed that the statement on impact of audit qualifications is not required as the auditors did not express any modified opinion or reservation.

For the quarter ended March 31, 2026, the company reported a net profit of ₹21.22 crore on a revenue from operations of ₹756.56 crore. Total income for the quarter was ₹767.41 crore, with total expenses amounting to ₹720.53 crore. The basic and diluted earnings per share for the quarter were ₹0.13, while for the full year, they stood at ₹1.71.

Financial Performance

The following table summarizes the key financial figures for the quarter and year ended March 31, 2026:

Segment Reporting

The company operates through two primary business segments: Pharma Division and Chemical Division. For the year ended March 31, 2026, the Pharma Division reported a revenue of ₹1,896.33 crore, while the Chemical Division contributed ₹943.19 crore. The Pharma Division recorded a segment profit before tax of ₹235.90 crore, whereas the Chemical Division reported a profit of ₹94.69 crore.

Operational Updates

The company noted that manufacturing operations were partially disrupted during the year due to renovation and upgradation work at the factory, necessitated by a revision in Schedule M of the Drug & Cosmetics Rules. This disruption resulted in a decline in turnover compared to the previous year. Additionally, the net profit for the year increased due to the disposal of an undertaking situated at Sanwer Road Industrial Area, Indore, to Formo Plast Private Limited.

The company submitted newspaper clippings of the publication of these audited financial results to the stock exchanges on June 1, 2026. The results were published in Free Press Mumbai & Indore (English) and Choutha Sansar (Hindi) on May 31, 2026.